Venture capital

When AI stands for augmented intelligence

By using technology to expose human blind spots, we can improve decision-making – but only if we ensure these systems remain transparent and accountable

January Capital founding partners Jason Edwards (left) and Benjamin Dunphy. The firm says that its Growth Credit Fund aims to fill a “critical capital gap” in Asia-Pacific.

January Capital’s private credit fund marks final close at over US$130 million

The fund offers growth-stage, sponsor-backed tech firms in Apac less-dilutive financing through senior secured loans

The speed with which AI-driven companies can create value is forcing VC fund managers to rethink long-standing frameworks for early-stage investment.

How AI is forcing VCs to rethink their timelines

[SINGAPORE] There’s a lot of talk about how much generative AI has changed the startup game, but what’s less discussed is the extent of the sector’s impact on venture capital itself.

In the past three decades, Singaporean venture capitalist Jenny Lee has proven her mettle with her trailblazing spirit.

How Jenny Lee became Asia’s ‘Iron Woman’ of venture capital

She is also a frequent presence in global top 100 most influential women lists

(From left) HSBC's senior leaders Jonathan Yip, Gilbert Ng, David Sabow and Neil Falconer at the launch of HSBC Innovation Banking with the bank's clients. The lender will set aside US$1.5 billion to support this new banking segment.

HSBC brings startup-focused Innovation Banking to Singapore, allocates US$1.5 billion to finance high-growth companies

Lender will execute a go-to-market strategy that covers both entrepreneurs and venture capital firms

Compared with other industries, biotech startups typically have long and uncertain timelines, as well as high capital requirements – all of which translate into perceived higher risk.

Challenging economic conditions raise the bar for nascent biotech startups as funding dries up

The pullback in science and tech funding in the US has cooled investor sentiment for now, but observers say more money may eventually flow into Asia and Europe

The impact of Trump’s pharma tariffs on drugmakers is evident, but the upstream implications for startups developing novel drugs are less clear.

Singapore draws international biotech VCs as Asia-Pacific life sciences sector takes off

Trump’s tariffs may prompt firms to reassess investments, but the sector’s long-term outlook is unlikely to change

Nvidia CEO Jensen Huang is among several high-profile Silicon Valley executives who accompanied US President Donald Trump on a state visit to the UK this week.

Nvidia to invest in UK firms including Wayve, Revolut

The chipmaker’s financing is one of a slew of AI announcements from US technology companies this week, coinciding with Trump’s visit

China has accounted for over 75% of regional venture capital and private equity funding since 2019, and now contributes 26.7% of all drugs in the global development pipeline – up from 23.6% the year before, says Bain & Company.

China’s biotech boom: Collaboration, not competition, for Singapore

While China dominates global drug development, Singapore’s strength lies in bridging Asian innovation with Western capital, say industry players